TITLE

Oral Glucose Loading for Detection of Mitochondrial Toxicity During HAART in HIV-Infected Patients

AUTHOR(S)
Ter Hofstede, Hadewych J. M.; Borm, George F.; Koopmans, Peter P.
PUB. DATE
October 2007
SOURCE
Current HIV Research;Oct2007, Vol. 5 Issue 4, p389
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Nucleoside reverse transcriptase inhibitors used in antiretroviral therapy may cause mitochondrial toxicity. Mitochondrial dysfunction leads to disturbance of the glucose metabolism, resulting in an accumulation of L-lactate. We tested the hypothesis that an oral glucose tolerance test (OGTT) can be used to detect mitochondrial toxicity in patients on antiretroviral nucleoside analogues. An OGTT was performed in 30 subjects: 16 HIV-infected treated patients without adverse events (group 1) and 14 HIV-infected patients with adverse events related to nucleoside reverse transcriptase inhibitor- induced mitochondrial toxicity (group 2). Lactate was measured at baseline and 60 and 120 min after glucose loading. At all time points the lactate levels were higher in the adverse events group compared to the other group, with the highest levels of lactate at t = 60 min (mean 1912 �mol/L, SD � 609); mean lactates in the group without adverse events was 1429 �mol/L (SD � 464). When levels above the upper limit of normal of 1800 �mol/L were used as an indication for mitochondrial toxicity, the sensitivity and specificity were 57% and 81%, respectively. The area under the ROC curve was 0.75. For L-lactate levels > 2000 �mol/L the specificity was 90%. An OGTT with measurement of lactate at baseline and one hour after glucose loading can detect (occult) hyperlactataemia in patients with mitochondrial impairment. From our study we suggest to perform an OGTT as an additional test in patients with symptoms suspect for adverse events to discern mitochondrial toxicity.
ACCESSION #
25534717

 

Related Articles

  • Five-Year Outcomes of the China National Free Antiretroviral Treatment Program.  // Annals of Internal Medicine;8/18/2009, Vol. 151 Issue 4, pI-42 

    The article presents a study on the rate of recovery of patients in the National Free Antiretroviral Treatment Program in China after five years. It notes that 48,785 patients with HIV were enrolled in the program under the highly active antiretroviral therapy. It mentions that after 6 months of...

  • Some HIV patients treated during early infection test negative. Iversen, John // Bay Area Reporter;7/22/2004, Vol. 34 Issue 30, p19 

    Reports that some HIV patients who received antiretroviral therapy early after infection test negative for HIV. Findings by researchers from the San Francisco, California-based University of California; Implications for HIV care and treatment.

  • Self-reported signs of lipodystrophy by persons living with HIV infection. Dreezen, C.; Schrooten, W.; De Mey, I.; Goebel, F. D.; Dedes, N.; Florence, E.; Colebunders, R.; Eurosupport Study Group // International Journal of STD & AIDS;Jun2002, Vol. 13 Issue 6, p393 

    Objective: To identify risk factors for the development of lipodystrophy in HIV infected patients on highly active antiretroviral therapy.Methods: A survey among patients with HIV infection using an anonymous questionnaire was conducted in 10 European countries between...

  • Reduced adherence to antiretroviral therapy among patients on antiretroviral therapy in Limpopo province, South Africa. MAKUA, T. // African Journal for Physical, Health Education, Recreation & Dan;2015Supplement, Vol. 21, p107 

    The purpose of this study was to explore the determining factors for reduced adherence to antiretroviral therapy (ART) for HIV positive patients on ART residing in Polokwane, in Limpopo Province of South Africa. This study made use of the generic qualitative research design and in-depth...

  • This antiviral offers new option to HIV patients. Beyzarov, Elena // Drug Topics;8/7/2006, Vol. 150 Issue 15, p12 

    The article features Prezista as the new protease inhibitor. Prezista is under the generic name darunavir. It is prescribed for the treatment of HIV in patients who had experienced antiretroviral treatment. It is designed to tackle viral strains that are resistant to one or more protease...

  • Successive switching of antiretroviral therapy is associated with high psychological and physical burden. Sherr, Lorraine; Lampe, Fiona; Norwood, Sally; Leake-Date, Heather; Fisher, Martin; Edwards, Simon; Arthur, Gilly; Anderson, Jane; Zetler, Sarah; Johnson, Margaret; Harding, R. // International Journal of STD & AIDS;Oct2007, Vol. 18 Issue 10, p700 

    HIV treatment and management is constantly evolving. This is as a result of more treatment options coming on stream, tolerance changes and progress in treatment management. HIV infection today, in resource-rich countries and in the presence of combination therapies, is experienced as lifelong...

  • More research needed to determine risks of efavirenz treatment among children.  // Infectious Disease News;Jul2014, Vol. 27 Issue 7, p46 

    The article reports that a review in the "Journal of Pediatric Health, Medicine and Therapeutics" stressed the need for more research on the actual risks of treating children with HIV-1 with efavirenz.

  • Considerations for Initiating Therapy for the Patient with Asymptomatic HIV Infection.  // MMWR: Morbidity & Mortality Weekly Report;5/17/2002 Supplement RR-7, Vol. 51 Issue 19, p5 

    Discusses the considerations for initiating antiretroviral therapy for patients with asymptomatic HIV infection. Potential benefits and risks of early therapy; Potential benefits and risks of early and delayed therapy; Factors that must be considered in deciding to begin therapy for the...

  • TRIAL WILL EVALUATE CYCLOSPORINE.  // AIDS Patient Care & STDs;Mar1999, Vol. 13 Issue 3, p202 

    Announces the recruitment of HIV patients with CD4 cell counts above 500 for a phase II placebo-controlled study of low-dose cyclosporine. Anecdotal reports of the potential of the immunosuppressant as an HIV treatment; Duration of the trial.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics